Lung Cancer

Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.

Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.

The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.

The phase 3 DeLLphi-305 trial found that the first-line maintenance therapy improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared with durvalumab alone.

Tarlatamab targets DLL3 in lung cancer; learn step-up dosing, CRS/ICANS monitoring, and pharmacy tips to keep patients safely on therapy.

First-line trastuzumab deruxtecan significantly delayed disease progression in HER2-mutant advanced NSCLC.

Timed clinician prompts plus patient reminders boost annual LDCT follow-up to 75%, highlighting workflow fixes that close lung cancer screening gaps.

Pafolacianine enables fluorescence-guided lung cancer surgery, with inpatient pharmacy integral to safe procurement, preparation, and interdisciplinary coordination.

World Lung Cancer Day presents an opportunity to recognize progress in lung cancer care while emphasizing the persistent need for earlier detection and equitable access to treatment.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

GSK's next-generation ROS1 inhibitor earns approval after demonstrating durable responses in the ARROS-1 trial, including among patients with brain metastases.

Baseline proton pump inhibitor (PPI) use and, to a lesser extent, antibiotic use were associated with reduced benefit from consolidation durvalumab after chemoradiotherapy in patients with unresectable stage 3 NSCLC.

Researchers found that excess abdominal fat suppresses immune surveillance in the lungs by increasing regulatory T cells, challenging the "obesity paradox."

Candel Therapeutics has launched the global phase 3 AURORA trial to evaluate investigational viral immunotherapy in patients with advanced non–small cell lung cancer.

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.

At ASCO 2026, CHRYSALIS-2 data show amivantamab plus lazertinib extends survival in atypical EGFR-mutated NSCLC, reshaping first-line care.

Heavy marijuana smoking may increase lung cancer risk, with cannabis use disorder linked to higher odds of small cell and non–small cell disease.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

A study finds that nearly half of older adults with mNSCLC do not receive treatment despite major advances in immunotherapy and targeted therapies that can improve survival and quality of life.

Advanced lung cancer inflammation index (ALI) predicts 3‑month recovery after thrombolysis for acute ischemic stroke, with low ALI signaling higher risk.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices such as cemiplimab, and access tips for treating non–small cell lung cancer.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

Keytruda Qlex is a subcutaneous formulation of pembrolizumab that offers a faster, more convenient alternative to IV administration with comparable efficacy.